Chemotherapy of Secondary Leukemias.

Select Content Type
eBooks
Authored By
Visani, Giuseppe
Authored On
Interests
Emergency Medicine
ENT
Surgery
Speciality
Surgery
Emergency Medicine
ENT
Book Detail
volume
37
ISSN
10428194
Publication Date
Actions
Download in App
Event Data
{"title":"Ear, Nose, and Throat Diseases","subtitle":"With Head and Neck Surgery","e_issn":null,"url":"https:\/\/research.ebsco.com\/c\/tyhpwl\/search\/results?q=AN+4205909&db=nlebk","series":"","edition":"4","author":"Hans Behrbohm-Oliver Kaschke-Tadeus Nawka-Andrew C. Swift","contract_publisher":"Thieme Medical Publishing Inc.","imprint_publisher":"Thieme","pub_year":"2023","interest_area":["ENT"," Emergency Medicine"," Surgery"],"lcc":"RF56","lcsh":"Handbook,Head--surgery,Neck--surgery,Otorhinolaryngologic Diseases,Otorhinolaryngologic Surgical Procedures--method","language":"eng","format":"EPUB,PDF","downloadable":"TRUE","fiction":"FALSE","abridged":"","book_id":"4205909","isbn":"9783136712047","eisbn":"9783131702142","ocn":"1519446215","ddc":"617.5","isPdfLink":true,"isSAML":false,"additionalInfo":{"Authored_By":"Visani, Giuseppe","Subjects":"Cancer chemotherapy, Leukemia, Therapeutics, Immune response","Languages":"English","Published_Date":"2000-05-01","Title_Abbreviations":"Leukemia & Lymphoma","Volume":"37"},"header":{"DbId":"asr","DbLabel":"STM Source","An":"4205909","RelevancyScore":"1279","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"1278.94836425781"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=asr&AN=4205909&authtype=shib&custid=ns346513&group=main&profile=eds","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=asr&AN=4205909&authtype=shib&custid=ns346513&group=main&profile=eds"}
ISSN
9783136712047
IS_Ebsco
true
Additional Info
["Visani, Giuseppe","Cancer chemotherapy, Leukemia, Therapeutics, Immune response","English","2000-05-01","Leukemia & Lymphoma","37"]
Description
Examines the efficacy of secondary leukemia chemotherapy. Effect of using a high dose of ara-C on immune resistance; Prognostic factors to be considered for response and disease-free survival following therapy; Observation of a higher incidence of poor prognostic characteristics associated with treatment resistance or failure.
Published Date